According to a recent LinkedIn post from Loyal, the company has completed a $100M Series C financing led by age1 with participation from Baillie Gifford and existing investors, bringing total capital raised to more than $250M. The post suggests that the proceeds are intended to support the transition of LOY-002, its lead program focused on lifespan extension for senior dogs, from late-stage development toward potential market readiness.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post indicates that, if ultimately approved by the FDA, LOY-002 could become the first drug authorized to extend lifespan in any species, highlighting a potentially significant regulatory milestone in veterinary and longevity medicine. For investors, this funding round may reduce near-term financing risk, strengthen Loyal’s position in the emerging pet longevity segment, and, if clinical and regulatory outcomes are favorable, create a differentiated first-mover advantage in a high-margin companion-animal therapeutics niche.
The post also references an interview with Founder & CEO Celine Halioua in Fast Company discussing the implications of this funding milestone and progress toward longevity drugs for dogs. While commercial timelines, pricing, and adoption dynamics remain uncertain and contingent on FDA approval, the scale and caliber of investors in the round may be interpreted as external validation of the company’s scientific approach and market opportunity, potentially supporting higher private-market valuations and future capital access.